<DOC>
	<DOC>NCT00140062</DOC>
	<brief_summary>The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.</brief_summary>
	<brief_title>Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Unilateral or bilateral openangle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension IOP of &gt; 21 mm Hg on current treatment Any previous or current treatment with latanoprost or other prostaglandin analogues</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>